As part of ongoing efforts to improve our quality of service, LifeLabs BC has implemented a new analytical platform for clinical immunoassay-based urine drug screens, and for blood glucose-6-Phosphate dehydrogenase and serum/plasma/red blood cell cholinesterase testing. With this, our labs in British Columbia will continue to serve as one of the few reference testing sites in the province for these specialized tests.
We have aligned our instrumentation and reviewed our test offerings to best match what the current needs are for screening. Fentanyl is now added due to the increased prevalence in unregulated drug supplies and associated risk to patients, and Buprenorphine is now part of the test panel as we have seen an increased use of it in primary care as a safe alternative in opioid replacement therapy.
Furthermore, will switch to the Siemens Atellica CH 930 instruments to remain current with national technology standards and ensure we continue to offer quality service to our customers.
Overall, the new platform will help LifeLabs remain current with national standards for laboratory technology, which will support our overall goal in ensuring we continue to provide quality testing services for our customers.
If you have any questions, please contact: 1-800-431-7206.
